RhumbLine Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-61,220
| Closed | -$3.6M | – | 4301 |
|
|
2023
Q4 | $3.6M | Buy |
61,220
+9,349
| +18% | +$526K | ﹤0.01% | 1601 |
|
|
2023
Q3 | $2.26M | Buy |
51,871
+424
| +0.8% | +$15.1K | ﹤0.01% | 1795 |
|
|
2023
Q2 | $1.86M | Buy |
51,447
+3,010
| +6% | +$124K | ﹤0.01% | 1949 |
|
|
2023
Q1 | $1.8M | Sell |
48,437
-817
| -2% | -$36.7K | ﹤0.01% | 1857 |
|
|
2022
Q4 | $2.23M | Buy |
49,254
+3,091
| +7% | +$200K | ﹤0.01% | 1721 |
|
|
2022
Q3 | $3.22M | Buy |
46,163
+7,021
| +18% | +$520K | ﹤0.01% | 1497 |
|
|
2022
Q2 | $2.63M | Buy |
39,142
+3,608
| +10% | +$229K | ﹤0.01% | 1623 |
|
|
2022
Q1 | $2.92M | Sell |
35,534
-2,921
| -8% | -$299K | ﹤0.01% | 1610 |
|
|
2021
Q4 | $5.64M | Buy |
38,455
+2,178
| +6% | +$338K | 0.01% | 1287 |
|
|
2021
Q3 | $6.42M | Sell |
36,277
-932
| -3% | -$150K | 0.01% | 1203 |
|
|
2021
Q2 | $6.01M | Sell |
37,209
-11,934
| -24% | -$1.92M | 0.01% | 1328 |
|
|
2021
Q1 | $8.42M | Sell |
49,143
-4,650
| -9% | -$921K | 0.01% | 1102 |
|
|
2020
Q4 | $11.8M | Buy |
53,793
+6,715
| +14% | +$1.45M | 0.02% | 822 |
|
|
2020
Q3 | $7.82M | Sell |
47,078
-9,597
| -17% | -$1.31M | 0.01% | 893 |
|
|
2020
Q2 | $6.47M | Buy |
56,675
+15,398
| +37% | +$1.49M | 0.01% | 1044 |
|
|
2020
Q1 | $3.17M | Buy |
41,277
+3,307
| +9% | +$297K | 0.01% | 1290 |
|
|
2019
Q4 | $4.89M | Buy |
37,970
+2,465
| +7% | +$238K | 0.01% | 1265 |
|
|
2019
Q3 | $2.77M | Buy |
35,505
+2,015
| +6% | +$189K | 0.01% | 1553 |
|
|
2019
Q2 | $3.45M | Buy |
33,490
+6,126
| +22% | +$477K | 0.01% | 1405 |
|
|
2019
Q1 | $2.01M | Buy |
27,364
+1,123
| +4% | +$76.4K | ﹤0.01% | 1714 |
|
|
2018
Q4 | $1.11M | Buy |
26,241
+9,385
| +56% | +$374K | ﹤0.01% | 1953 |
|
|
2018
Q3 | $794K | Buy |
16,856
+86
| +0.5% | +$4.79K | ﹤0.01% | 2098 |
|
|
2018
Q2 | $827K | Buy |
+16,770
| New | +$633K | ﹤0.01% | 2099 |
|
|
2017
Q2 | – | Sell |
-16,954
| Closed | -$88K | – | 2969 |
|
|
2017
Q1 | $88K | Buy |
16,954
+5,325
| +46% | +$29.2K | ﹤0.01% | 2787 |
|
|
2016
Q4 | $55K | Sell |
11,629
-1,458
| -11% | -$7.93K | ﹤0.01% | 2824 |
|
|
2016
Q3 | $87K | Buy |
13,087
+100
| +0.8% | +$532 | ﹤0.01% | 2822 |
|
|
2016
Q2 | $71K | Buy |
12,987
+1,890
| +17% | +$30.1K | ﹤0.01% | 2947 |
|
|
2016
Q1 | $237K | Buy |
11,097
+130
| +1% | +$2.91K | ﹤0.01% | 2650 |
|
|
2015
Q4 | $347K | Buy |
10,967
+2,330
| +27% | +$82.3K | ﹤0.01% | 2481 |
|
|
2015
Q3 | $297K | Buy |
8,637
+392
| +5% | +$11.8K | ﹤0.01% | 2544 |
|
|
2015
Q2 | $259K | Buy |
+8,245
| New | +$243K | ﹤0.01% | 2752 |
|
Other funds holding MRTX
RhumbLine Advisers's MRTX Position: Q1 2024 in Review
RhumbLine Advisers sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 61,220 shares — an estimated $3.6M sold.
RhumbLine Advisers first reported a position in MRTX in Q2 2015 and held it in 31 quarters. The position peaked at $11.8M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- RhumbLine Advisers reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- RhumbLine Advisers sold 61,220 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.6M.
- RhumbLine Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 31 quarters.
- RhumbLine Advisers's Mirati Therapeutics, Inc. Common Stock position peaked at $11.8M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on RhumbLine Advisers's 13F filing for Q1 2024, filed 9 May 2024.